MA50448A - Dérivés sulfonamides aromatiques pour le traitement d'un accident cérébral ischémique - Google Patents
Dérivés sulfonamides aromatiques pour le traitement d'un accident cérébral ischémiqueInfo
- Publication number
- MA50448A MA50448A MA050448A MA50448A MA50448A MA 50448 A MA50448 A MA 50448A MA 050448 A MA050448 A MA 050448A MA 50448 A MA50448 A MA 50448A MA 50448 A MA50448 A MA 50448A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- ischemic cerebral
- cerebral injury
- sulphonamide derivatives
- aromatic sulphonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199070 | 2017-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50448A true MA50448A (fr) | 2020-09-02 |
Family
ID=60191221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050448A MA50448A (fr) | 2017-10-29 | 2018-10-24 | Dérivés sulfonamides aromatiques pour le traitement d'un accident cérébral ischémique |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210179577A1 (fr) |
| EP (1) | EP3700891A1 (fr) |
| JP (1) | JP2021501178A (fr) |
| KR (1) | KR20200081445A (fr) |
| CN (1) | CN111511720A (fr) |
| AU (1) | AU2018356430A1 (fr) |
| BR (1) | BR112020008484A2 (fr) |
| CA (1) | CA3079469A1 (fr) |
| CL (1) | CL2020001139A1 (fr) |
| EA (1) | EA202091028A1 (fr) |
| IL (1) | IL274041A (fr) |
| JO (1) | JOP20200077A1 (fr) |
| MA (1) | MA50448A (fr) |
| MX (1) | MX2020004472A (fr) |
| SG (1) | SG11202003565PA (fr) |
| WO (1) | WO2019081573A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3458443T3 (pl) * | 2016-05-03 | 2021-03-08 | Bayer Pharma Aktiengesellschaft | Aromatyczne pochodne sulfonamidowe |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| EP4172146A1 (fr) | 2020-06-30 | 2023-05-03 | Bayer Aktiengesellschaft | N-phénylacétamides substitués ayant une activité antagoniste du récepteur p2x4 |
| WO2022049253A1 (fr) | 2020-09-07 | 2022-03-10 | Bayer Aktiengesellschaft | N-hétéroaryl-n-pyridinylacétamides substitués en tant que modulateurs de p2x4 |
| WO2022161416A1 (fr) * | 2021-01-27 | 2022-08-04 | 武汉朗来科技发展有限公司 | Composé aromatique, son procédé de préparation et son application |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| CN102753535B (zh) * | 2009-09-03 | 2015-03-25 | 百时美施贵宝公司 | 作为钾离子通道抑制剂的喹唑啉 |
| US20130023534A1 (en) | 2010-03-26 | 2013-01-24 | Casillas Linda N | Pyrazolyl-pyrimidines as kinase inhibitors |
| KR101871436B1 (ko) | 2010-05-17 | 2018-06-27 | 인코젠 쎄라퓨틱스 프라이빗 리미티드 | 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물 |
| WO2015088565A1 (fr) | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | Composés modulateurs du récepteur p2x4 et leurs procédés d'utilisation |
| WO2015088564A1 (fr) | 2013-12-13 | 2015-06-18 | Sunovion Pharmaceuticals Inc. | Composés modulateurs du récepteur p2x4 |
| CN107848974A (zh) * | 2015-06-10 | 2018-03-27 | 拜耳制药股份公司 | 芳族磺酰胺衍生物 |
| PL3458443T3 (pl) * | 2016-05-03 | 2021-03-08 | Bayer Pharma Aktiengesellschaft | Aromatyczne pochodne sulfonamidowe |
-
2018
- 2018-10-24 US US16/759,970 patent/US20210179577A1/en not_active Abandoned
- 2018-10-24 CN CN201880084317.4A patent/CN111511720A/zh active Pending
- 2018-10-24 JO JOP/2020/0077A patent/JOP20200077A1/ar unknown
- 2018-10-24 MA MA050448A patent/MA50448A/fr unknown
- 2018-10-24 MX MX2020004472A patent/MX2020004472A/es unknown
- 2018-10-24 CA CA3079469A patent/CA3079469A1/fr not_active Abandoned
- 2018-10-24 AU AU2018356430A patent/AU2018356430A1/en not_active Abandoned
- 2018-10-24 EP EP18793635.6A patent/EP3700891A1/fr not_active Withdrawn
- 2018-10-24 EA EA202091028A patent/EA202091028A1/ru unknown
- 2018-10-24 KR KR1020207015477A patent/KR20200081445A/ko unknown
- 2018-10-24 SG SG11202003565PA patent/SG11202003565PA/en unknown
- 2018-10-24 JP JP2020524149A patent/JP2021501178A/ja active Pending
- 2018-10-24 WO PCT/EP2018/079145 patent/WO2019081573A1/fr active Application Filing
- 2018-10-24 BR BR112020008484-0A patent/BR112020008484A2/pt not_active Application Discontinuation
-
2020
- 2020-04-19 IL IL274041A patent/IL274041A/en unknown
- 2020-04-29 CL CL2020001139A patent/CL2020001139A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020008484A2 (pt) | 2020-10-20 |
| CL2020001139A1 (es) | 2020-10-23 |
| IL274041A (en) | 2020-06-30 |
| JP2021501178A (ja) | 2021-01-14 |
| CA3079469A1 (fr) | 2019-05-02 |
| KR20200081445A (ko) | 2020-07-07 |
| JOP20200077A1 (ar) | 2020-04-30 |
| EA202091028A1 (ru) | 2020-09-09 |
| SG11202003565PA (en) | 2020-05-28 |
| EP3700891A1 (fr) | 2020-09-02 |
| AU2018356430A1 (en) | 2020-04-30 |
| WO2019081573A9 (fr) | 2020-05-28 |
| CN111511720A (zh) | 2020-08-07 |
| US20210179577A1 (en) | 2021-06-17 |
| MX2020004472A (es) | 2020-08-06 |
| WO2019081573A1 (fr) | 2019-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50448A (fr) | Dérivés sulfonamides aromatiques pour le traitement d'un accident cérébral ischémique | |
| MA45052A (fr) | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille | |
| FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| MA45041A (fr) | Polynucléotides codant pour la galactose-1-phosphate uridylyltransférase destinés au traitement de la galactosémie de type 1 | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA51046A (fr) | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| HK1253734A1 (zh) | 用作RORγ激動劑和用於治療疾病的芳基二氫-2H-苯並[B][1，4]噁嗪磺酰胺和相關化合物 | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA48583A (fr) | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques | |
| MA50441A (fr) | Nouvelle association d'agents actifs pour le traitement de pneumopathies interstitielles fibrosantes progressives (pf-ild) | |
| MA47207A (fr) | Composés utiles pour le traitement de troubles du tractus digestif | |
| MA55917A (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
| MA53375A (fr) | Dispositifs d'administration pour l'administration de médicaments | |
| MA52888A (fr) | Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques | |
| MA41629A (fr) | Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité | |
| MA44065A (fr) | Composés sulfonamides de dihydroquinoline d'alkyle | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques | |
| EP3709968C0 (fr) | Émulsions destinés au traitement d'infections vaginales | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| MA53636A (fr) | Agent de traitement de troubles dermatologiques | |
| MA51413A (fr) | Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique | |
| MA43001A (fr) | Cannabidiol et hu-211 pour le traitement d'une lésion cérébrale traumatique |